REPLIGEN CORP RGEN

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

References throughout this Form 10-K to "Repligen Corporation", "Repligen", "we", "us", "our", or the "Company" refer to Repligen Corporation and its subsidiaries, taken as a whole, unless the context otherwise indicates.

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs.

As the overall market for biologics continues to grow and expand, our primary customers – global biopharmaceutical companies, contract development and manufacturing organizations and other life science companies (integrators) – face critical production cost, capacity, quality and time pressures. Built to address these concerns, our products help set new standards for the way biologics are manufactured. We are committed to inspiring advances in bioprocessing as a trusted partner in the production of critical biologic drugs – including monoclonal antibodies ("mAbs") and mAb derivatives like antibody drug conjugates, recombinant proteins, RNA-based therapeutics and vaccines and cell and gene therapies ("C&GT") – that are improving human health worldwide.

Last close 176.93 2026-10-23
Market cap $9.99B 2026-06-30 share count
52-week range 100.99 - 198.87

Valuation FY2025 figures against the last close

P/S13.5x
P/E205.7x
P/FCF106.3x
EV/EBITDA102.9x
Dividend yield—
Diluted EPS0.86

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $738.3M$634.4M$632.4M$801.5M$670.5M$366.3M$270.2M$194.0M$141.2M$104.5M
Cost of revenue $352.0M$359.8M$353.9M$345.8M$279.3M$156.6M$119.1M$86.5M$67.0M$47.1M
Gross profit $386.2M$274.6M$278.4M$455.7M$391.3M$209.6M$151.1M$107.5M$74.2M$57.4M
R&D $54.2M$43.2M$42.7M$43.9M$34.3M$20.2M$19.4M$15.8M$8.7M$7.4M
SG&A $290.5M$263.4M$218.6M$215.8M$183.9M$119.6M$95.6M$65.7M$51.5M$30.9M
Total operating expenses $683.1M$669.6M$584.7M$576.9M$503.3M$296.4M$234.2M$168.0M$127.2M$88.6M
Operating income $55.2M-$35.1M$47.7M$224.7M$167.2M$69.8M$36.1M$26.0M$14.0M$16.0M
Interest expense $21.5M$20.7M$2.5M$1.2M$11.3M$10.8M$9.3M$6.7M$6.4M$3.8M
Pre-tax income $62.4M-$27.0M$56.7M$219.1M$153.5M$59.2M$26.2M$21.4M$7.2M$11.7M
Income tax $13.5M$1.5M$21.1M$33.2M$25.3M$709.0K$4.7M$4.8M$21.1M$11.0K
Net income $48.9M-$25.5M$35.6M$186.0M$128.3M$59.9M$21.4M$16.6M$28.4M$11.7M
EPS, basic 0.87-0.460.643.352.331.140.440.380.740.35
EPS, diluted 0.86-0.460.633.242.241.110.440.370.720.34
Shares, diluted (wtd. avg.) 56,56155,93756,37757,45557,26453,89249.2M45.5M39.1M34,099

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $566.0M$757.4M$751.3M$523.5M$603.8M$717.3M$537.4M$193.8M$173.8M$122.7M
Short-term investments $201.6M$0—————$0$0—
Receivables $158.6M$134.1M$124.2M$116.2M$117.4M$71.4M$43.1M$33.0M$27.6M$15.2M
Inventory $170.5M$143.0M$202.3M$238.3M$184.5M$95.0M$54.8M$42.3M$39.0M$24.7M
Total current assets $1.14B$1.07B$1.11B$998.1M$931.7M$902.4M$641.8M$275.7M$242.8M$184.2M
Property, plant and equipment $186.6M$197.7M$207.4M$190.7M$125.0M$66.9M$48.5M$32.2M$22.4M$15.0M
Goodwill $1.11B$1.03B$987.1M$855.5M$860.4M$618.3M$468.4M$326.7M$327.3M$59.5M
Other intangibles $386.1M$397.9M$407.0M$360.6M$337.3M$287.1M$212.6M$135.4M$144.8M$29.8M
Total assets $2.95B$2.83B$2.83B$2.53B$2.36B$1.90B$1.40B$774.6M$743.5M$288.9M
Accounts payable $30.0M$32.1M$19.6M$27.6M$36.2M$16.9M$11.4M$10.5M$7.3M$5.1M
Total current liabilities $135.8M$126.8M$164.9M$404.2M$375.3M$319.0M$48.3M$129.8M$25.2M$21.1M
Long-term debt $542.2M$525.6M————————
Total liabilities $843.6M$856.9M$866.3M$620.9M$608.3M$373.7M$340.3M$159.1M$152.0M—
Retained earnings $456.2M$407.4M$432.9M$397.3M$194.1M$65.8M$5.8M-$677.0K-$31.5M-$59.9M
Total equity $2.11B$1.97B$1.96B$1.91B$1.75B$1.53B$1.06B$615.6M$591.5M$168.8M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $117.4M$175.4M$113.9M$172.1M$119.0M$62.6M$67.2M$32.8M$17.5M$7.5M
Depreciation and amortisation $39.7M$35.0M$37.0M$23.9M$16.4M$10.9M$7.3M$5.2M$4.2M$3.3M
Stock-based compensation $32.6M$48.1M$25.6M$27.3M$27.5M$17.0M$12.8M$10.2M$6.7M$4.6M
Capital expenditure $23.5M$25.7M$36.2M$84.8M$67.1M$22.5M$18.5M$10.6M$5.5M$4.3M
Investing cash flow -$298.5M-$86.4M-$123.3M-$233.2M-$221.2M-$201.4M-$205.3M-$14.0M-$98.7M-$49.2M
Financing cash flow -$15.2M-$82.9M$249.0M-$13.3M$961.0K$305.9M$484.9M$3.4M$129.9M$112.1M
Buybacks $0$0$14.4M$0$0—————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-076528.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -250M 0 250M 500M 750M 1B Revenue, FY2016: 104.5M Gross profit, FY2016: 57.4M Net income, FY2016: 11.7M Revenue, FY2017: 141.2M Gross profit, FY2017: 74.2M Net income, FY2017: 28.4M Revenue, FY2018: 194M Gross profit, FY2018: 107.5M Net income, FY2018: 16.6M Revenue, FY2019: 270.2M Gross profit, FY2019: 151.1M Net income, FY2019: 21.4M Revenue, FY2020: 366.3M Gross profit, FY2020: 209.6M Net income, FY2020: 59.9M Revenue, FY2021: 670.5M Gross profit, FY2021: 391.3M Net income, FY2021: 128.3M Revenue, FY2022: 801.5M Gross profit, FY2022: 455.7M Net income, FY2022: 186M Revenue, FY2023: 632.4M Gross profit, FY2023: 278.4M Net income, FY2023: 35.6M Revenue, FY2024: 634.4M Gross profit, FY2024: 274.6M Net income, FY2024: -25.5M Revenue, FY2025: 738.3M Gross profit, FY2025: 386.2M Net income, FY2025: 48.9M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $104.5M $141.2M $194.0M $270.2M $366.3M $670.5M $801.5M $632.4M $634.4M $738.3M
Gross profit $57.4M $74.2M $107.5M $151.1M $209.6M $391.3M $455.7M $278.4M $274.6M $386.2M
Net income $11.7M $28.4M $16.6M $21.4M $59.9M $128.3M $186.0M $35.6M -$25.5M $48.9M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Results announced Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%